P. Cortazar

发表

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Gideon Blumenthal, Nina Ditsch, David Cameron, 2014, The Lancet.

First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer

R. Pazdur, B. Rellahan, P. Cortazar, 2013, Clinical Cancer Research.

Summary : Sunitinib for the Treatment of Progressive Well-Differentiated Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors

R. Pazdur, A. Murgo, P. Cortazar, 2012 .

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group.

Caroline Schenkel, L. Fehrenbacher, N. Roach, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second lung cancers in patients successfully treated for lung cancer.

B. Johnson, J. Chute, P. Cortazar, 1997, Seminars in oncology.

FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.

R. Pazdur, A. Murgo, P. Cortazar, 2012, The Oncologist.

US Food and Drug Administration approval overview in metastatic breast cancer.

P. Keegan, R. Pazdur, P. Cortazar, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer.

B. Johnson, P. Cortazar, B. Johnson, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.

I. Wistuba, P. Hwu, S. Woodman, 2021, Cancer discovery.

Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis

A. Schneeweiss, S. Swain, C. Jackisch, 2022, Cancers.

Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)

P. Fasching, C. Perou, J. Bergh, 2012 .

Pathological complete response in breast cancer – Authors' reply

C. Geyer, D. Cameron, L. Gianni, 2015, The Lancet.

Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing.

S. Steinberg, A. Gazdar, E. Russell, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

L. Ellis, C. Sima, D. Sargent, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Developing drugs to decrease the toxicity of chemotherapy.

R. Pazdur, P. Cortazar, R Pazdur, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

S. J. Schrieber, R. Pazdur, A. Russell, 2014, Clinical Cancer Research.

First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer

R. Pazdur, L. Amiri-Kordestani, P. Cortazar, 2014, Clinical Cancer Research.

A phase II trial of atezolizumab and bevacizumab in patients with advanced, progressive neuroendocrine tumors (NETs).

P. A. Futreal, I. Wistuba, P. Bhosale, 2020 .

Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge.

A. Schneeweiss, E. Perez, M. Piccart, 2021, Cancer treatment reviews.

Neoadjuvant breast cancer therapy and drug development.

P. Cortazar, P. Kluetz, 2015, Clinical advances in hematology & oncology : H&O.

Neoadjuvant Breast Cancer Trials: Translational Research in Drug Development

Reena Philip, L. Amiri-Kordestani, P. Cortazar, 2015, Current Breast Cancer Reports.

Pathological Complete Response in Neoadjuvant Treatment of Breast Cancer

C. Geyer, P. Cortazar, 2015, Annals of Surgical Oncology.

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer

R. Pazdur, R. Charlab, Todd R. Palmby, 2015, Clinical Cancer Research.

Abstract S1-11: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)

P. Fasching, C. Perou, J. Bergh, 2012 .

Overestimation of the Effect Size in Group Sequential Trials

P. Cortazar, G. Blumenthal, R. Sridhara, 2012, Clinical Cancer Research.

Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC).

R. Pazdur, P. Cortazar, R. Justice, 2010, The oncologist.

NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.

C. Denkert, J. Costantino, C. Geyer, 2018 .

Potential of Neoadjuvant Trials to Support Drug Approval in High-Risk Early Breast Cancer

P. Cortazar, Tatiana M. Prowell, Lijun Zhang, 2014 .

FDA evaluation of hepatotoxicity related to tyrosine kinase inhibitors.

I. Zineh, R. Pazdur, P. Cortazar, 2011, Journal of Clinical Oncology.

Treatment Patterns and Mortality Risk among Elderly Patients with Metastatic Triple Negative Breast Cancer in the United States: An Observational Cohort Study Using SEER-Medicare Data

P. Cortazar, A. Stein, C. Reyes, 2019, Journal of Cancer Therapy.

Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors.

R. Pazdur, P. Cortazar, R. Justice, 2010, The oncologist.

Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy

A. Schneeweiss, R. Gelber, M. Buyse, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exposure–Response Relationship of T‐DM1: Insight Into Dose Optimization for Patients With HER2‐Positive Metastatic Breast Cancer

S. J. Schrieber, Yow-Ming C Wang, P. Cortazar, 2014, Clinical pharmacology and therapeutics.

Increased Mortality Risk among Early Stage Hormone Receptor Positive Breast Cancer Patients Who Did Not Receive Adjuvant or Neoadjuvant Therapy

P. Cortazar, A. Stein, C. Reyes, 2019, Journal of Cancer Therapy.

Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

A. Schneeweiss, R. Gelber, M. Buyse, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC): Pooled-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC).

J. Costantino, C. Geyer, N. Wolmark, 2014, Journal of Clinical Oncology.

Metastatic breast cancer (MBC): FDA approval overview

R. Pazdur, P. Cortazar, R. Justice, 2008 .

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

L. Ellis, C. Sima, D. Sargent, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Which patient characteristics drive treatment decisions in elderly patients with early stage hormone receptor–positive breast cancer?

P. Cortazar, A. Stein, C. Reyes, 2017 .

Adjuvant breast cancer: FDA approval overview.

R. Pazdur, P. Cortazar, R. Justice, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.